Vejle Hospital

Running trials

• Not yet recruiting

  Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer

  NCT07903883· Source

• Not yet recruiting

  Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies

  NCT07878208· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Source

• Recruiting

  Prehabilitation to Patients With Prostate Cancer

  NCT07162987· Source

• Recruiting

  SMARTER: Using Blood Samples to iMprove FIT-bAsed coloRecTal cancEr scReening

  NCT06714318· Source

• Recruiting

  Understanding and Tailored Treatment of Low Anterior Resection Syndrome

  NCT07573371· Source

• Recruiting

  Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

  NCT06505369· Phase 2· Source

• Active, not recruiting

  VIsualization of Coronary Artery Disease for Modification of RISK Factors

  NCT06413641· Source

• Active, not recruiting

  A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  NCT05936359· Phase 1· Source

• Recruiting

  DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies

  NCT06076811· Source

• Active, not recruiting

  The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

  NCT03129490· Phase 4· Source

• Recruiting

  FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer

  NCT05810701· Source

• Active, not recruiting

  A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04628494· Phase 3· Source

• Recruiting

  A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

  NCT04332822· Phase 3· Source

• Recruiting

  The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer

  NCT04291378· Source

• Active, not recruiting

  First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

  NCT03625037· Phase 1/2· Source

• Active, not recruiting

  Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

  NCT02170090· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer5 recruiting
• Multiple myeloma2 recruiting
• Heart failure1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  2022-502457-34-00· Phase 2· Source

• Completed

  MRI T1 Relaxation Time in Rectal Cancer

  NCT05876026· Source

• Completed

  Spinal Anaesthesia vs. General Anaesthesia for THA, TKA and UKA

  NCT05706844· Phase 4· Source

• Completed

  Clinical trial on Spinal Anaesthesia vs. General Anaesthesia (SAGA) on recovery after hip and knee replacements

  2022-501221-21-00· Phase 4· Source

• Completed

  Implementation of Smoking Cessation Support During Lung Cancer Workup

  NCT05192031· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Completed

  Shared Decision Making With Anal Cancer Patients on Radiation Dose

  NCT02785263· Source